Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1749-6632.1988.tb36340.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DNA Methyltransferase Inhibition Upregulates the Costimulatory Molecule ICAM-1 and the Immunogenic Phenotype of Melanoma Cells.
JID Innov
March 2025
Department of Dermatology, University Hospital of Zurich, University of Zurich, Schlieren, Switzerland.
In cutaneous melanoma, epigenetic dysregulation is implicated in drug resistance and tumor immune escape. However, the epigenetic mechanisms that influence immune escape remain poorly understood. To elucidate how epigenetic dysregulation alters the expression of surface proteins that may be involved in drug targeting and immune escape, we performed a 3-dimensional surfaceome screen in primary melanoma cultures and identified the DNA-methyltransferase inhibitor decitabine as significantly upregulating the costimulatory molecule ICAM-1.
View Article and Find Full Text PDFFactors affecting the efficacy of human leukocyte antigen-selected platelet provision: A large retrospective study in the United Kingdom.
Transfus Med
January 2025
Histocompatibility & Immunogenetics, NHSBT Colindale Centre, London, UK.
Background: A large, retrospective study was designed to interrogate current NHS Blood and Transplant (NHSBT) HLA matching strategies for the provision of HLA selected platelets (HLA SP) and to determine whether additional factors such as ABO blood group matching, patient diagnosis, patient and/or donor age, sex, ethnicity, age of platelet unit at transfusion and possibly seasonal variation also play a role in transfusion efficacy.
Materials And Methods: Data for 56 640 HLA SP transfusions over a 3-year period were collected. Transfusions with missing data for any factor under consideration were excluded, resulting in a cohort of 13 044 transfusions for analysis.
Identification of the Novel HLA-A*03:01:01:122 Allele in a Chinese Individual Using PacBio HiFi Sequencing.
HLA
October 2024
Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Article Synopsis
- - The text discusses a specific variant of the HLA-A gene called HLA-A*03:01:01:122.
- - This variant differs from another variant, HLA-A*03:01:01:01, by a single nucleotide alteration.
- - The change occurs in intron 3 of the gene, which is a non-coding region between the exons.
Identification of three new HLA-A intronic variants by next-generation sequencing.
HLA
October 2024
Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA)-Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
Three novel HLA-A intronic variants, HLA-A*03:01:01:121, HLA-A*29:02:01:41 and HLA-A*30:02:01:24, detected by next-generation sequencing.
View Article and Find Full Text PDFNatural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors.
J Clin Invest
September 2024
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Article Synopsis
- - The study investigates T cell responses to KRAS mutations, particularly the KRASG12V variant, and focuses on T cell receptors (TCRs) that are specific to this mutation within certain HLA class I alleles.
- - It reports on a clinical vaccine trial that successfully primed both CD8+ and CD4+ T cell responses against KRASG12V, revealing that natural TCRs showed high specificity and effectiveness in targeting mutated cancer cells without affecting normal cells.
- - The findings suggest a strong therapeutic potential for these KRASG12V-specific TCRs in developing targeted T cell therapies, highlighting their ability to effectively attack tumors even with low levels of antigen presentation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!